Extraintestinal pathogenic Escherichia coli: An update on antimicrobial resistance, laboratory diagnosis and treatment

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 10, 2012, Pages 1165-1176

  Pitout, Johann D D ^a,b  

^a CALGARY LABORATORY SERVICES   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

carbapenemases; CTX M lactamases; ExPEC; extraintestinal pathogenic Escherichia coli; KPC; laboratory detection; NDM; OXA 48; plasmid mediated AmpC lactamases; treatment options

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; BETA LACTAMASE CTX M; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; CLAVULANIC ACID; CLOXACILLIN; COLISTIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; METALLO BETA LACTAMASE; MONOBACTAM; NITROFURANTOIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; SULFONAMIDE; TAZOBACTAM; TEMOCILLIN; TRIMETHOPRIM; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; ENTEROBACTERIACEAE; ESCHERICHIA COLI INFECTION; EXTRAINTESTINAL PATHOGENIC ESCHERICHIA COLI; HOSPITAL INFECTION; HUMAN; INTESTINE INFECTION; LABORATORY DIAGNOSIS; MORBIDITY; MORTALITY; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PATHOGENIC ESCHERICHIA COLI; PLASMID; PNEUMONIA; REVIEW; SEPSIS; SURGICAL INFECTION; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84870592622     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.110     Document Type: Review

References (94)

1. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2(2), 123-140 (2004).
2. Herzer PJ, Inouye S, Inouye M, Whittam TS. Phylogenetic distribution of branched RNA-linked multicopy single-stranded DNA among natural isolates of Escherichia coli. J. Bacteriol. 172(11), 6175-6181 (1990).
3. Mokady D, Gophna U, Ron EZ. Virulence factors of septicemic Escherichia coli strains. Int. J. Med. Microbiol. 295(6-7), 455-462 (2005).
4. Wiles TJ, Kulesus RR, Mulvey MA. Origins and virulence mechanisms of uropathogenic Escherichia coli. Exp. Mol Pathol. 85(1), 11-19 (2008).
5. Foxman B. The epidemiology of urinary tract infection. Nat. Rev. Urol. 7(12), 653-660 (2010).
6. Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 14(9), 413-420 (2006).
7. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl. J. Med. 352(4), 380-391 (2005).
8. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerging Infect. Dis. 17(10), 1791-1798 (2011).
9. Sullivan CB, Diggle MA, Clarke SC. Multilocus sequence typing: data analysis in clinical microbiology and public health. Mol. Biotechnol. 29(3), 245-254 (2005).
10. Mushtaq S, Irfan S, Sarma JB et al Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J. Antimicrob. Chemother. 66(9), 2002-2005 (2011).
11. Peirano G, Ahmed-Bentley J, Woodford N, Pitout JD. New Delhi metallo-beta-lactamase from traveler returning to Canada. Emerging Infect. Dis. 17(2), 242-244 (2011).
12. Peirano G, van der Bij AK, Gregson DB, Pitout JD. Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum ß-lactamase- producing Escherichia coli causing bacteremia in a centralized Canadian region. J. Clin. Microbiol. 50(2), 294-299 (2012).
13. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18 (4), 657-686 (2005).
14. Cantón R, Coque TM. The CTX-M beta-lactamase pandemic. Curr. Opin. Microbiol. 9(5), 466-475 (2006).
15. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8(3), 159-166 (2008).
16. Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int. J. Antimicrob. Agents 35 (4), 316-321 (2010).
17. Pitout JD, Gregson DB, Campbell L, Laupland KB. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob. Agents Chemother. 53(7), 2846-2851 (2009).
18. Johnson JR, Nicolas-Chanoine MH, DebRoy C et al. MASTER Investigators. Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009. Emerging Infect. Dis. 18 (4), 598-607 (2012).
19. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob. Agents Chemother. 53(7), 2733-2739 (2009).
20. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin. Infect. Dis. 51(3), 286-294 (2010).
21. Suzuki S, Shibata N, Yamane K, Wachino J, Ito K, Arakawa Y. Change in the prevalence of extended-spectrum-beta-lactamase-producing Escherichia coli in Japan by clonal spread. J. Antimicrob. Chemother. 63(1), 72-79 (2009).
22. van der Bij AK, Peirano G, Goessens WH, van der Vorm ER, van Westreenen M, Pitout JD. Clinical and molecular characteristics of extended-spectrum-beta- lactamase-producing Escherichia coli causing bacteremia in the Rotterdam Area, Netherlands. Antimicrob. Agents Chemother. 55 (7), 3576-3578 (2011).
23. Kim J, Bae IK, Jeong SH, Chang CL, Lee CH, Lee K. Characterization of IncF plasmids carrying the blaCTX-M-14 gene in clinical isolates of Escherichia coli from Korea. J. Antimicrob. Chemother. 66(6), 1263-1268 (2011).
24. Mshana SE, Imirzalioglu C, Hain T, Domann E, Lyamuya EF, Chakraborty T. Multiple ST clonal complexes, with a predominance of ST131, of Escherichia coli harbouring bla CTX-M-15 in a tertiary hospital in Tanzania. Clin. Microbiol. Infect. 17(8), 1279-1282 (2011).
25. Coque TM, Novais A, Carattoli A et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerging Infect. Dis. 14(2), 195-200 (2008).
26. Jones GL, Warren RE, Skidmore SJ, Davies VA, Gibreel T, Upton M. Prevalence and distribution of plasmid-mediated quinolone resistance genes in clinical isolates of Escherichia coli lacking extended-spectrum beta-lactamases. J. Antimicrob. Chemother. 62(6), 1245-1251 (2008).
27. Mihaila L, Wyplosz B, Clermont O et al. Probable intrafamily transmission of a highly virulent CTX-M-3-producing Escherichia coli belonging to the emerging phylogenetic subgroup D2 O102-ST405 clone. J. Antimicrob. Chemother. 65(7), 1537-1539 (2010).
28. Smet A, Martel A, Persoons D et al. Characterization of extended-spectrum beta-lactamases produced by Escherichia coli isolated from hospitalized and nonhospitalized patients: emergence of CTX-M-15-producing strains causing urinary tract infections. Microb. Drug Resist. 16(2), 129-134 (2010).
29. Cortés P, Blanc V, Mora A et al. Isolation and characterization of potentially pathogenic antimicrobial-resistant Escherichia coli strains from chicken and pig farms in Spain. Appl. Environ. Microbiol. 76(9), 2799-2805 (2010).
30. Zong Z, Yu R. Escherichia coli carrying the b l a C T X-M-15 gene of ST648. J. Med. Microbiol. 59(Pt 12), 1536-1537 (2010).
31. Van der Bij AK, Peirano G, Pitondo-Silva A, Pitout JD. The presence of genes encoding for different virulence factors in clonally related Escherichia coli that produce CTX-Ms. Diagn. Microbiol. Infect. Dis. 72(4), 297-302 (2012).
32. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG; Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42(5), 657-668 (2006).
33. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type beta-lactamases. Antimicrob. Agents Chemother. 46(1), 1-11 (2002).
34. Doi Y, Paterson DL. Detection of plasmid-mediated class C beta-lactamases. Int. J. Infect. Dis. 11(3), 191-197 (2007).
35. Ding H, Yang Y, Lu Q et al. The prevalence of plasmid-mediated AmpC beta-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae from fve children's hospitals in China. Eur. J. Clin. Microbiol. Infect. Dis. 27(10), 915-921 (2008).
36. Li Y, Li Q, Du Y et al. Prevalence of plasmid-mediated AmpC beta-lactamases in a Chinese university hospital from 2003 to 2005: frst report of CMY-2-Type AmpC beta-lactamase resistance in China. J. Clin. Microbiol. 46(4), 1317-1321 (2008).
37. Moland ES, Hanson ND, Black JA, Hossain A, Song W, Thomson KS. Prevalence of newer beta-lactamases in Gram-negative clinical isolates collected in the United States from 2001 to 2002. J. Clin. Microbiol. 44(9), 3318-3324 (2006).
38. Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004). Int. J. Antimicrob. Agents 28(6), 578-581 (2006).
39. Woodford N, Reddy S, Fagan EJ et al. Wide geographic spread of diverse acquired AmpC beta-lactamases among Escherichia coli and Klebsiella spp. in the UK and Ireland. J. Antimicrob. Chemother. 59(1), 102-105 (2007).
40. Alvarez M, Tran JH, Chow N, Jacoby GA. Epidemiology of conjugative plasmid-mediated AmpC beta-lactamases in the United States. Antimicrob. Agents Chemother. 48(2), 533-537 (2004).
41. Mulvey MR, Bryce E, Boyd DA et al. Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob. Agents Chemother. 49(1), 358-365 (2005).
42. Pai H, Kang CI, Byeon JH et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48(10), 3720-3728 (2004).
43. Pitout JD, Gregson DB, Church DL, Laupland KB. Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary. Emerging Infect. Dis. 13(3), 443-448 (2007).
44. Varma JK, Marcus R, Stenzel SA et al. Highly resistant Salmonella Newport-MDRAmpC transmitted through the domestic US food supply: a FoodNet case-control study of sporadic Salmonella Newport infections, 2002-2003. J. Infect. Dis. 194(2), 222-230 (2006).
45. Pitout JD, Reisbig MD, Mulvey M et al. Association between handling of pet treats and infection with Salmonella enterica serotype newport expressing the AmpC beta-lactamase, CMY-2. J. Clin. Microbiol. 41(10), 4578-4582 (2003).
46. Hanson ND, Moland ES, Hong SG, Propst K, Novak DJ, Cavalieri SJ. Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community. Antimicrob. Agents Chemother. 52(10), 3814-3816 (2008).
47. Qin X, Zerr DM, Weissman SJ et al. Prevalence and mechanisms of broad-spectrum beta-lactam resistance in Enterobacteriaceae: a children's hospital experience. Antimicrob. Agents Chemother. 52(11), 3909-3914 (2008).
48. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin. Microbiol. Rev. 20(3), 440-458 (2007).
49. Walther-Rasmussen J, Høiby N. Class A carbapenemases. J. Antimicrob. Chemother. 60(3), 470-482 (2007).
50. Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). Diagn. Microbiol. Infect. Dis. 56(4), 367-372 (2006).
51. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9(4), 228-236 (2009).
52. Naas T, Cuzon G, Villegas M V, Lartigue MF, Quinn JP, Nordmann P. Genetic structures at the origin of acquisition of the beta-lactamase blaKPC gene. Antimicrob. Agents Chemother. 52(4), 1257-1263 (2008).
53. Poirel L, Pitout JD, Nordmann P. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol. 2(5), 501-512 (2007).
54. Cornaglia G, Akova M, Amicosante G et al.; ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS). Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int. J. Antimicrob. Agents 29(4), 380-388 (2007).
55. Yong D, Toleman MA, Giske CG et al. Characterization of a new metallo-beta-lactamase gene, bla (NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53(12), 5046-5054 (2009).
56. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10(9), 597-602 (2010).
57. Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. Early dissemination of NDM-1-and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrob. Agents Chemother. 55 (3), 1274-1278 (2011).
58. Castanheira M, Mendes RE, Woosley LN, Jones RN. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09).J. Antimicrob. Chemother. 66 (6), 1409-1411 (2011).
59. Lascols C, Hackel M, Marshall SH et al. Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). J. Antimicrob. Chemother. 66(9), 1992-1997 (2011).
60. Seema K, Ranjan Sen M, Upadhyay S, Bhattacharjee A. Dissemination of the New Delhi metallo-β-lactamase-1 (NDM-1) among Enterobacteriaceae in a tertiary referral hospital in north India. J. Antimicrob. Chemother. 66(7), 1646-1647 (2011).
61. Deshpande P, Rodrigues C, Shetty A, Kapadia F, Hedge A, Soman R. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised. J. Assoc. Physicians India 58, 147-149 (2010).
62. Perry JD, Naqvi SH, Mirza IA et al. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. J. Antimicrob. Chemother. 66(10), 2288-2294 (2011).
63. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends Microbiol. 19 (12), 588-595 (2011).
64. Leverstein-Van Hall MA, Stuart JC, Voets GM, Versteeg D, Tersmette T, Fluit AC. Global spread of New Delhi metallo-β-lactamase 1. Lancet Infect. Dis. 10 (12), 830-831 (2010).
65. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect. Dis. 11 (5), 355-362 (2011).
66. Peirano G, Schreckenberger PC, Pitout JD. Characteristics of NDM-1-producing Escherichia coli isolates that belong to the successful and virulent clone ST131. Antimicrob. Agents Chemother. 55(6), 2986-2988 (2011).
67. Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48(1), 15-22 (2004).
68. Carrër A, Poirel L, Yilmaz M et al. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob. Agents Chemother. 54(3), 1369-1373 (2010).
69. Cuzon G, Naas T, Bogaerts P, Glupczynski Y, Huang TD, Nordmann P. Plasmid-encoded car bapenem-hydroly zing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. Antimicrob. Agents Chemother. 52(9), 3463-3464 (2008).
70. Glupczynski Y, Huang TD, Bouchahrouf W et al. Rapid emergence and spread of OXA-48-producing carbapenem-resistant Enterobacteriaceae isolates in Belgian hospitals. Int. J. Antimicrob. Agents 39(2), 168-172 (2012).
71. Poirel L, Bonnin RA, Nordmann P. Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. Antimicrob. Agents Chemother. 56(1), 559-562 (2012).
72. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement. Wayne, PA, USA (2009).
73. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement. Wayne, PA, USA (2012).
74. Naas T, Cuzon G, Truong H, Bernabeu S, Nordmann P. Evaluation of a DNA microarray, the check-points ESBL/KPC array, for rapid detection of TEM, SHV, and CTX-M extended-spectrum beta-lactamases and KPC carbapenemases. Antimicrob. Agents Chemother. 54(8), 3086-3092 (2010).
75. Pitout JD, Le PG, Moore KL, Church DL, Gregson DB. Detection of AmpC beta-lactamases in Escherichia coli, Klebsiella spp., Salmonella spp. and Proteus mirabilis in a regional clinical microbiology laboratory. Clin. Microbiol. Infect. 16 (2), 165-170 (2010).
76. Brolund A, Wisell KT, Edquist PJ, Elfström L, Walder M, Giske CG. Development of a real-time SYBRGreen PCR assay for rapid detection of acquired AmpC in Enterobacteriaceae. J. Microbiol. Methods 82(3), 229-233 (2010).
77. Pérez-Pérez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol. 40(6), 2153-2162 (2002).
78. Nordmann P, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V; European Network on Carbapenemases. Identifcation and screening of carbapenemase-producing Enterobacteriaceae. Clin. Microbiol. Infect. 18(5), 432-438 (2012).
79. Girlich D, Poirel L, Nordmann P. Value of the modifed Hodge test for detection of emerging carbapenemases in Enterobacteriaceae. J. Clin. Microbiol. 50(2), 477-479 (2012).
80. Naas T, Cuzon G, Bogaerts P, Glupczynski Y, Nordmann P. Evaluation of a DNA microarray (Check-MDR CT102) for rapid detection of TEM, SHV, and CTX-M extended-spectrum β-lactamases and of KPC, OXA-48, VIM, IMP, and NDM-1 carbapenemases. J. Clin. Microbiol. 49(4), 1608-1613 (2011).
81. Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by Gram-negative bacilli. Clin. Infect. Dis. 41(6), 848-854 (2005).
82. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin. Infect. Dis. 32 (8), 1162-1171 (2001).
83. Tumbarello M, Sanguinetti M, Montuori E et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta- lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob. Agents Chemother. 51(6), 1987-1994 (2007).
84. Pitout JD. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 70(3), 313-333 (2010).
85. Rodríguez-Baño J, Pascual A. Clinical signifcance of extended-spectrum beta-lactamases. Expert Rev. Anti. Infect. Ther. 6(5), 671-683 (2008).
86. Laupland KB, Church DL, Vidakovich J, Mucenski M, Pitout JD. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J. Infect. 57(6), 441-448 (2008).
87. Zahar JR, Lortholary O, Martin C, Potel G, Plesiat P, Nordmann P. Addressing the challenge of extended-spectrum beta-lactamases. Curr. Opin. Investig Drugs 10(2), 172-180 (2009).
88. Titelman E, Iversen A, Kahlmeter G, Giske CG. Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. APMIS 119(12), 853-863 (2011).
89. Titelman E, Iversen A, Kalin M, Giske CG. Effcacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum ß-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb. Drug Resist. 18(2), 189-192 (2012).
90. Lampri N, Galani I, Poulakou G et al. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. J. Antimicrob. Chemother. (2012).
91. Schultsz C, Geerlings S. Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy. Drugs 72(1), 1-16 (2012).
92. Giamarellou H. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int. J. Antimicrob. Agents 36(Suppl. 2), S50-S54 (2010).
93. Stone NR, Woodford N, Livermore DM et al. Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-β-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis. J. Antimicrob. Chemother. 66(11), 2677-2678 (2011).
94. Pitout JD. Extraintestinal pathogenic Escherichia coli: a combination of virulence with antibiotic resistance. Front. Microbiol. 3, 9 (2012).